NCT03086564View on ClinicalTrials.gov

A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

May 1, 2020

Study Completion Date

October 29, 2020

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

ADCC & TACE

Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2\*10\^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.

PROCEDURE

TACE

TACE solely in the first day of a clinical course.

Trial Locations (1)

510630

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Yuehua Huang

OTHER

NCT03086564 - A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT) | Biotech Hunter | Biotech Hunter